CollPlant

Company Overview

Snapshot

Founded in August 2004 by Oded Shoseyov, CollPlant operates with 51–200 employees. The company has raised a total of $93.65 million across 16 funding rounds from 7 investors. In June 2026, CollPlant announced a $2.6 million private placement.

Business overview

CollPlant is a regenerative and aesthetic medicine company that develops technologies and products for tissue regeneration and organ manufacturing. The company's core technology leverages a plant-based platform for the mass production of recombinant human Type I collagen (rhCollagen), which is identical to human-produced collagen. CollPlant utilizes this rhCollagen and its biomaterial expertise to develop a pipeline of products for 3D bioprinting of tissues and organs, as well as medical aesthetics. It operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In October 2025, CollPlant's rhCollagen-based bioink, Collink.3D™, demonstrated strong performance compared to Matrigel® in a study conducted by Technion - Israel Institute of Technology. This validation from a reputable research institution highlights the potential superiority and efficacy of CollPlant's proprietary bioink, signaling a significant advancement in biomaterial science and strengthening the company's position in the regenerative medicine market.

Company Intelligence Q&A

What was a significant recent development regarding CollPlant's rhCollagen-based bioink?

In October 2025, CollPlant's rhCollagen-based bioink, Collink.3D™, demonstrated strong performance compared to Matrigel® in a study conducted by Technion - Israel Institute of Technology.

What was CollPlant's latest funding activity?

In June 2026, CollPlant announced a $2.6 million private placement. The funding type was PIPE (Private Investment in Public Equity).

What was the outcome of non-clinical studies for CollPlant's photocurable regenerative dermal and soft tissue filler?

In September 2025, CollPlant Biotechnologies announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler.

Did CollPlant expand its product distribution in Europe?

In September 2025, CollPlant expanded the distribution of its VergenixSTR product in Europe.

What was a key development in 3D bioprinting using CollPlant's technology?

In October 2025, Mayo Clinic researchers developed a first-in-kind fully humanized 3D bioprinted human skin model using CollPlant's rhCollagen-based BioInk.